Tirzepatide

From Retapedia, the free peptide encyclopedia
"Tirzepatide" redirects here. For other uses, see Tirzepatide (disambiguation).
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Tirzepatide (also known as Tirzepatide or GIP/GLP-1 dual agonist) is a therapeutically researched peptide studied for its effects on fat loss, weight loss, diabetes. FDA-approved dual GIP/GLP-1 agonist (Mounjaro/Zepbound) with superior 21% weight loss, first OSA medication, excellent diabetes control. GI side effects common.

Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly as Mounjaro (type 2 diabetes, 2.5-15mg weekly) and Zepbound (obesity and obstructive sleep apnea, 2.5-15mg weekly). Unique imbalanced agonist with greater GIP receptor engagement than GLP-1, plus biased GLP-1 agonism favoring cAMP generation over β-arrestin recruitment, enhancing insulin secretion. SURMOUNT trials demonstrated exceptional weight loss: 20.9% at 72 weeks (15mg dose), with 50-57% of participants achieving ≥20% weight loss.

Natty status
Tirzepatide is generally regarded as compatible with natural bodybuilding, though competitive federations may differ. See § Natty status.
Contents [hide]
  1. 1 Overview
  2. 2 Mechanism of action
  3. 3 Reported effects
  4. 4 Dosage and administration
  5. 5 Natty status
  6. 6 Research
  7. 7 Related compounds
  8. 8 References
  9. 9 External links

Overview

SURMOUNT-4 showed 25.3% mean weight reduction long-term.

Unprecedented diabetes efficacy in SURPASS trials with HbA1c reductions of 1.9-2.6% and weight loss of 6.6-13.9kg, superior to semaglutide 1mg.

December 2024 FDA approval as first medication for moderate-to-severe obstructive sleep apnea in adults with obesity, reducing breathing disruptions by 25-29 per hour (5x more effective than placebo).

Cardiovascular meta-analysis showed HR 0.80 for MACE-4, with SURPASS-4 showing HR 0.50 at 15mg dose.

Common side effects are gastrointestinal (nausea, vomiting, diarrhea 16.24% vs 8.63% placebo), typically mild-to-moderate, transient, occurring during dose escalation. 2024 systematic review found no association with pancreatitis.

Gradual titration every 4 weeks (2.5mg steps) minimizes adverse events.

Available in 6 strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg.

Mechanism of action

Reduces appetite for 21% weight loss. Significantly improves blood sugar and diabetes. Reduces sleep apnea breathing disruptions by 50%.

Reported effects

Effects reported in the literature and from preclinical models include:

  • Tirzepatide, a dual GIP/GLP-1 receptor agonist, delivers unprecedented glycemic control and weight reduction in type 2 diabetes and obesity, with monitoring required for gastrointestinal events, rare gallbladder and thyroid disorders, and skeletal muscle mass changes. [5] Phase III
  • Response to tirzepatide varies substantially between individuals and is predicted by clinical factors (dose, diabetes duration, beta-cell function, baseline HbA1c, sex, age, race) as well as genetic variants in GLP-1 and GIP receptors and molecular biomarkers. [6] Phase III
  • In obese patients with heart failure with preserved or mildly reduced ejection fraction, tirzepatide reduces heart failure hospitalizations and improves symptoms and functional capacity. [4] Phase III
  • In a meta-analysis of 11 RCTs comprising 13,378 participants, tirzepatide had a neutral overall effect on heart failure risk, though monotherapy and patients aged 58 or younger showed roughly a 57-60% relative risk reduction; results support its cardiovascular safety in T2DM and obesity. [1] Phase III
  • Tirzepatide is a reviewed pharmacotherapy option for obesity management in breast cancer survivors experiencing tamoxifen-associated weight gain who cannot achieve sufficient results with lifestyle interventions alone. [3] Phase III
  • Pooled RCT evidence does not demonstrate a statistically significant increase in thyroid cancer risk with incretin-based therapies including tirzepatide, though limited follow-up and rare events prevent excluding a clinically relevant increase. [7] Phase III
  • Despite high clinical efficacy, tirzepatide has a higher incremental cost-effectiveness ratio than semaglutide in most economic analyses, making its cost-effectiveness context-dependent. [2] Phase III

Evidence grades: FDA approved Phase III Phase II Phase I Preclinical Anecdotal

Dosage and administration

⚠
Dosage information is included for encyclopedic purposes only. Retapedia does not provide medical advice. See Retapedia : Medical disclaimer.

General

  • Week 1-4: 2.5mg once weekly (subcutaneous, starting dose)
  • Week 5-8: 5.0mg once weekly
  • Week 9-12: 7.5mg once weekly (optional step)
  • Week 13-16: 10mg once weekly
  • Week 17-20: 12.5mg once weekly (optional step)
  • Week 21+: 15mg once weekly (maximum dose)
  • Escalate by 2.5mg every 4 weeks minimum
  • Do not increase faster than 2.5mg per 4 weeks

Maintenance

  • 5mg, 10mg, or 15mg based on response/tolerability

Available strengths

  • 2.5, 5, 7.5, 10, 12.5, 15mg per 0.5mL

Natty status

See also: Peptide § Natty status

Tirzepatide is generally regarded as compatible with the natty designation, particularly when used for therapeutic healing purposes. Opinions vary across natural bodybuilding federations, and athletes who compete should consult the rulebook of their respective sanctioning body.[8]

Research

121 active clinical trials on record — highest phase: Phase 4
View on ClinicalTrials.gov · fetched Jun 3, 2026

The peptide has been the subject of 16 studies and reference works collected on this site. The full bibliography is in § External links below.

Other peptides in this catalogue with overlapping mechanisms or status:

Ozempic Natty
Reduces appetite and slows digestion for 15-21% weight loss. Improves blood sugar control. Lowers heart attack and stroke risk by 20%.
Retatrutide Natty
Reduces appetite and boosts metabolism for 24% weight loss. Improves blood sugar, lowers cholesterol, normalizes liver fat in 90% of users.
BPC-157 Natty
Speeds healing of tendons, ligaments, muscles, and gut. Reduces inflammation and muscle soreness. Minimizes scar tissue formation.
CJC-1295 Natty
Increases growth hormone and IGF-1 for 6+ days per injection. Improves body composition, muscle recovery, and fat metabolism. Weekly dosing.

References

  1. ^ Heart failure meta-analysis
  2. ^ Cost-effectiveness analysis
  3. ^ Addressing Tamoxifen-Associated Weight Gain: Lifestyle and Pharmacotherapy Options. Recent review
  4. ^ [Glucagon-like peptide-1 agonists and heart failure]. Recent review
  5. ^ Tirzepatide data: safety always comes first! Recent review
  6. ^ Multidimensional Predictors of Tirzepatide Efficacy: Clinical, Genetic, and Molecular Biomarkers for Glycemic, Weight, and Organ Protection. Recent review
  7. ^ Incretin-Based Therapy and Thyroid Cancer Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Recent review
  8. a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

Categories: Peptides | Therapeutic peptides | Fat loss | Weight loss | Diabetes | Cardiovascular

This page was last edited on June 3, 2026, at 15:00 (UTC).

Research last reviewed on June 3, 2026.

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.